A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care.
Age
Hemodialysis
Phosphate binder
Phosphorus
Pill burden
Sucroferric oxyhydroxide
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
19
01
2022
accepted:
25
07
2022
pubmed:
12
8
2022
medline:
25
1
2023
entrez:
11
8
2022
Statut:
ppublish
Résumé
Despite the growing number of elderly hemodialysis patients, the influence of age on nutritional parameters, serum phosphorus (sP), and use of phosphate-binder (PB) medications has not been well characterized. We aimed to describe age-related differences in patient characteristics in a large, real-world cohort of maintenance hemodialysis patients, and to examine the impact of age on sP management with sucroferric oxyhydroxide (SO). We retrospectively analyzed de-identified data from 2017 adult, in-center hemodialysis patients who switched from another PB to SO monotherapy as part of routine clinical care. Changes in baseline PB pill burden, sP levels, and nutritional and dialytic clearance parameters were assessed across varying age groups through 6 months. At baseline, older patients had lower mean sP, serum albumin, and pre-dialysis weights compared with younger patients. Prescription of SO was associated with a 62% increase in the proportion of patients achieving sP ≤ 5.5 mg/dl and a 42% reduction in daily pill burden. The proportion of patients achieving sP ≤ 5.5 mg/dl after transitioning to SO increased by 113, 96, 68, 77, 61, 37 and 40% among those aged 19-29, 30-39, 40-49, 50-59, 60-69, 70-79, and ≥ 80 years, respectively. Older patients had worse nutritional parameters, lower pill burden, and lower sP at baseline versus younger counterparts. Prescription of SO was associated with improved sP control and reduced pill burden across all ages.
Identifiants
pubmed: 35953565
doi: 10.1007/s11255-022-03327-w
pii: 10.1007/s11255-022-03327-w
pmc: PMC9859895
doi:
Substances chimiques
Phosphorus
27YLU75U4W
sucroferric oxyhydroxide
0
Drug Combinations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
377-387Informations de copyright
© 2022. The Author(s).
Références
Circ Res. 2000 Sep 29;87(7):E10-7
pubmed: 11009570
Pediatr Nephrol. 2015 Dec;30(12):2061-71
pubmed: 25543193
Nephrol Dial Transplant. 2015 Jun;30(6):1037-46
pubmed: 25691681
BMC Nephrol. 2008 Jan 31;9:2
pubmed: 18237373
Kidney Int Suppl (2011). 2017 Jul;7(1):1-59
pubmed: 30675420
Nephrol Dial Transplant. 2013 Dec;28(12):2961-8
pubmed: 23901051
Am J Nephrol. 2018;47(3):153-161
pubmed: 29514139
Circ J. 2014;78(10):2339-46
pubmed: 25077548
Patient Prefer Adherence. 2018 Jul 04;12:1175-1191
pubmed: 30013329
J Ren Nutr. 2017 Sep;27(5):346-354
pubmed: 28550969
PLoS One. 2015 Dec 04;10(12):e0144119
pubmed: 26636968
J Am Soc Nephrol. 2004 Aug;15(8):2208-18
pubmed: 15284307
Am J Kidney Dis. 2012 Jul;60(1):90-101
pubmed: 22385781
Kidney Int. 2014 Sep;86(3):638-47
pubmed: 24646861
Am J Kidney Dis. 2008 Sep;52(3):519-30
pubmed: 18514987
Am J Kidney Dis. 2014 Jul;64(1):143-50
pubmed: 24819675
Nephrol Dial Transplant. 1999 Jul;14(7):1679-86
pubmed: 10435876
BMC Nephrol. 2019 Oct 29;20(1):396
pubmed: 31664928
Nephrol Dial Transplant. 2014 Nov;29(11):2092-9
pubmed: 24009281
N Engl J Med. 2009 Oct 15;361(16):1539-47
pubmed: 19828531
Clin J Am Soc Nephrol. 2011 Jul;6(7):1651-62
pubmed: 21734085
Clin J Am Soc Nephrol. 2009 Jun;4(6):1089-96
pubmed: 19423571
Clin Nephrol. 2017 Aug;88(8):59-67
pubmed: 28587714
Kidney Med. 2020 Mar 26;2(3):307-316
pubmed: 32734250
Kidney Int Rep. 2017 Oct 06;3(1):185-192
pubmed: 29340330
J Pediatr. 1986 May;108(5 Pt 1):767-70
pubmed: 3701525
Am J Nephrol. 2020;51(8):650-658
pubmed: 32739911
Pediatr Nephrol. 2021 May;36(5):1233-1244
pubmed: 33106892
Hemodial Int. 2016 Jan;20(1):38-49
pubmed: 25975222
J Ren Nutr. 2013 Nov;23(6):411-21
pubmed: 23631888
Calcif Tissue Int. 2021 Jan;108(1):116-127
pubmed: 31996964
PLoS One. 2017 Oct 3;12(10):e0185853
pubmed: 28973026
Pediatr Nephrol. 2018 Feb;33(2):325-333
pubmed: 28900759
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
Kidney Med. 2019 Sep 05;1(5):253-262
pubmed: 32734205
Curr Osteoporos Rep. 2017 Jun;15(3):198-206
pubmed: 28455644
Nat Rev Nephrol. 2020 Oct;16(10):573-585
pubmed: 32733095
J Ren Nutr. 2019 Sep;29(5):428-437
pubmed: 30679076
Am J Kidney Dis. 2006 Apr;47(4):625-35
pubmed: 16564940
J Am Soc Nephrol. 2021 Mar;32(3):526-528
pubmed: 33547217
Clin Kidney J. 2019 Jun 17;13(2):217-224
pubmed: 32296527
Kidney Int. 2007 Mar;71(5):438-41
pubmed: 17200680
BMC Nephrol. 2013 Oct 03;14:208
pubmed: 24090377
J Am Soc Nephrol. 2009 Feb;20(2):388-96
pubmed: 19092121
Int J Med Sci. 2011;8(7):628-34
pubmed: 22022216
Am J Kidney Dis. 2001 Jun;37(6):1260-6
pubmed: 11382697
J Nephrol. 2010 Sep-Oct;23(5):525-34
pubmed: 20119931
Clin Kidney J. 2019 Dec 05;14(1):348-357
pubmed: 33564438
J Nephrol. 2020 Jun;33(3):497-508
pubmed: 31865608
J Am Soc Nephrol. 2013 Feb;24(3):337-51
pubmed: 23264684
J Am Soc Nephrol. 2021 Mar;32(3):723-735
pubmed: 33547218
Pediatr Nephrol. 2010 Feb;25(2):373-5
pubmed: 19876653